33953-37-6

Basic information

• Product Name: N-PIPERIDIN-4-YL-BENZAMIDE
• Synonyms: 4-BENZIMIDO PIPERIDINE;4-BENZAMIDOPIPERIDINE HYDRATE;4-BENZOYLAMINOPIPERIDINE;BUTTPARK 154\06-76;N-(4-PIPERIDYL)BENZAMIDE;N-(4-PIPERIDYL)BENZAMIDE HYDRATE;N-(4-PIPERIDINYL)BENZAMIDE;N-PIPERIDIN-4-YL-BENZAMIDE
• CAS NO: 33953-37-6
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• EINECS: 251-759-1
• Product Categories: Amines;Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines
• Mol File: 33953-37-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 137 °C
• Boiling Point: 412.4ºC at 760 mmHg
• Flash Point: 174.8 ºC
• Appearance: /
• Density: 1.11 g/cm³
• Vapor Pressure: 5.26E-06mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: 2-8°C
• PKA: 14.35±0.20(Predicted)
• CAS DataBase Reference: N-PIPERIDIN-4-YL-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-PIPERIDIN-4-YL-BENZAMIDE(33953-37-6)
• EPA Substance Registry System: N-PIPERIDIN-4-YL-BENZAMIDE(33953-37-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 33953-37-6(Hazardous Substances Data)

Usage

Uses

N-(Piperidin-4-yl)benzamide is used in preparation of [(azaheterocyclyl)thiazolyl] heteroaryl ketones as vanin-1 inhibitors.

InChI:InChI=1/C12H16N2O/c13-12(15)11-3-1-9(2-4-11)10-5-7-14-8-6-10/h1-4,10,14H,5-8H2,(H2,13,15)

Upstream product

• 13035-19-3 4-aminopiperidine 
• 10364-94-0 1-benzoylimidazole 
• 35621-01-3 4-aminopiperidine dihydrochloride 
• 65-85-0 benzoic acid 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 98-88-4 benzoyl chloride 
• 4783-65-7 N-benzyl-2-piperidinone 
• 955050-02-9 tert-butyl 4-benzamidopiperidine-1-carboxylate 
• 971-34-6 1-benzyl-4-benzamidopiperidine 

Downstream Products

• 36793-55-2 2-[2-(4-benzoylamino-piperidin-1-yl)-acetylamino]-4-phenyl-thiazole-5-carboxylic acid ethyl ester 
• 36806-84-5 N-(1-{2-[4-(4-chloro-phenyl)-2-phenyl-thiazol-5-yl]-ethyl}-piperidin-4-yl)-benzamide 
• 92242-40-5 7-(4-Benzoylamino-piperidin-1-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 81580-30-5 N-[1-(2-Oxo-propyl)-piperidin-4-yl]-benzamide 
• 36793-62-1 1-[4-(4-Fluorophenyl)-4-oxobutyl]-4-benzamidopiperidine 
• 115076-65-8 (4-Benzoylamino-piperidin-1-yl)-acetic acid (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyl-dodecahydro-benzo[f]chromen-5-yl ester 
• 577778-27-9 1-Acetyl-4-benzamidopiperidin 
• 387825-73-2 2-[2-(4-benzamino-1-piperidyl)ethyl]-1,2,3,4-tetrahydro-1-oxo-naphthalene 
• 36793-39-2 1-Phenacyl-4-benzamidopiperidine 
• 52818-58-3 4-benzamido-1-(2-hydroxyethyl)piperidine 
• 36807-02-0 N-(1-benzo[1,3]dioxol-5-ylmethyl-piperidin-4-yl)-benzamide 
• 57642-91-8 4-(4-Benzamidopiperid-1-yl)-1,1-(di-p-fluorophenyl)but-1-ene 
• 58786-30-4 4-benzamido-1-[4-(indol-3-yl)-4-oxobutyl] piperidine 
• 1242436-69-6 N-{1-[3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-propyl]-piperidin-4-yl}-benzamide 

Relevant articles and documents

Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways

Guided by bioisosterism and pharmacokinetic parameters, we designed and synthesized a series of novel benzamide derivatives. Preliminary in vitro studies indicated that compounds 10b and 10j show significant inhibitory bioactivity in HepG2 cells (IC50 values of 0.12 and 0.13?μM, respectively). Compounds 10b and 10j induced the expression of HIF-1α protein and downstream target gene p21, and upregulated the expression of cleaved caspase-3 to promote tumor cells apoptosis.

Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An allosteric muscarinic M 1 receptor agonist with unprecedented selectivity and procognitive potential

The discovery and Structure-activity relationship (SAR) of a series of allosteric muscarinic M1 receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.